コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Median progression-free survival was 11.0 months (95% CI 10.4
2 Median progression-free survival was 11.0 months (95% CI 9.2-
3 Median progression-free survival was 11.1 months (95% CI 8.4-
4 Median progression-free survival was 12.6 months.
5 Median progression-free survival was 13.3 months (95% CI 9.9-
6 Median progression-free survival was 13.7 months (95% CI, 9.6
7 Median progression-free survival was 16.6 months (95% CI 13.8
8 Median progression-free survival was 18.4 months (95% CI 11.1
9 Median progression-free survival was 18.7 months (95% CI 15.6
10 Median progression-free survival was 2.0 months, not differen
11 Median progression-free survival was 2.1 months (95% CI, 1.1
12 Median progression-free survival was 2.1 months, and median o
13 Median progression-free survival was 2.7 months (2.1 to 4.2).
14 Median progression-free survival was 2.8 months (95% CI 2.8-3
15 Median progression-free survival was 3.48 months (95% CI 1.51
16 Median progression-free survival was 3.9 months (interquartil
17 Median progression-free survival was 3.9 months with pembroli
18 Median progression-free survival was 4.1 months for paclitaxe
19 Median progression-free survival was 4.6 months (95% CI 3.5-5
20 Median progression-free survival was 5.5 months (95% CI 5.4-5
21 Median progression-free survival was 5.6 months in the ipilim
22 Median progression-free survival was 8.7 months.
23 Median progression-free survival was 9.5 months (95% CI 9.2-1
24 In the total patient population (n=1147), median progression-free survival was 6.9 months (95% CI 6.8-7
25 At a median follow-up of 14 months (IQR 7-18), median progression-free survival was 20.8 months (95% CI 16.6
26 nths for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 mo
27 In PI3K pathway-activated patients (n=372), median progression-free survival was 6.8 months (95% CI 4.9-7
28 er a median observation time of 37.1 months (IQR 31.0-45.5) median progression-free survival was 41.7 months (95% CI 34.9
29 At a median follow-up of 48 months (IQR 31-56), median progression-free survival was 39 months (95% CI 35-44)
30 In patients with known PI3K status (n=851), median progression-free survival was 6.8 months (95% CI 5.0-7
32 sponse was not reached (95% CI, 16.7 to not estimable), and median progression-free survival was 14.2 months (95% CI, 8.3
33 (90%) of 174 patients in arm B had disease progression, and median progression-free survival was 9.9 months (95% CI 9.4-1
34 .2 months (IQR 8.5-17.3), the updated investigator-assessed median progression-free survival was 12.3 months (95% CI 9.5-
36 rvival of 68% (50-81), whereas in the T790M-negative group, median progression-free survival was 10.5 months (9.4-14.2),
38 Results Among patients who received nivolumab monotherapy, median progression-free survival was 3.0 months (95% CI, 2.2
39 With a median follow up of 25.7 months, median progression-free survival was 10.1 months (T,: 16.6 mo
40 Results At a minimum follow-up of 18 months, median progression-free survival was 8.4 months for patients
45 The median overall survival was 28.7 months, and the median progression-free survival was 14.1 months.
48 3 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivoluma
49 .98; p=0.037) and in the 48 patients with PTEN-low tumours, median progression-free survival was 6.2 months (95% CI 3.6-9
50 After a minimum follow-up of 6 years, median progression-free survival was 43 months and median dur
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。